← FDA DRUG APPROVALS

FDA ANDA · ANDA040433

LIDOCAINE

lidocaine hydrochloride

Sponsor: SENTISS

APPLICATION
ANDA040433
TYPE
ANDA
ORIGINAL APPROVAL
2003-02-12
LATEST ACTION
2025-08-27
ROUTE
TOPICAL
DOSAGE FORM
JELLY
MARKETING STATUS
Prescription

Products

LIDOCAINE HYDROCHLORIDEPrescription
LIDOCAINE HYDROCHLORIDE 2% · JELLY · TOPICAL

Approval history

2025-08-27Manufacturing (CMC) · Supplement 20 · unknownAP
2020-03-25Labeling · Supplement 14 · standardAP
2017-03-10Manufacturing (CMC) · Supplement 12 · unknownAP
2003-02-12OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →